Table 1.
Most-utilized vaccinations against COVID-19.
| Local/Given Name | Codename | Type | Origin: Company/Country | Approval/Authorization | Efficacy Trials Phase II/III/IV |
References |
|---|---|---|---|---|---|---|
| Pfizer | BNT162b2 Vaccine | Uridine nucleoside modified mRNA (encodes the receptor-binding domain or full-length version of SARS-CoV-2 spike protein) | BioNTech (Germany) in collaboration with Fosun Pharmaceuticals (Shanghai, China) and Pfizer (Canada) | FDA-approved; FDA Emergency Use Authorization (EUA); WHO-approved in 103 countries; among first vaccines to get EUA in December 2020 | 95% efficacy. Safe during pregnancy. 38 trials in 20 countries. Phase IV registered on 27 September 2021 |
[6,20,25,26,27,28,29,30] |
| Moderna | mRNA-1273 Vaccine | mRNA-based vaccine designed to express the coronavirus spike protein | Massachusetts (the United States) along with the National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority | FDA-approved; FDA (EUA); WHO-approved in 76 countries; among first vaccines to get EUA in December 2020 | 94% efficacy; safe during pregnancy. 31 trials in 7 countries; phase II in August 2021; phase IV launched in June 2021 |
[6,20,25,26,27,28,29,30] |
| Janssen | Ad26.COV2.S | Adenoviral-based vaccine | Johnson and Johnson/the United States, the Netherlands. | FDA-approved; FDA (EUA); WHO-approved in 75 countries | 13 trials in 3 countries. Phase IV launched in June 2021 |
[6,20,25,26,28] |
| AstraZeneca/Vaxzevria | AZD1222 Vaccine/ChAdOx1 | Chimpanzee Adenovirus-Vectored vaccine | Oxford University under British pharmaceutical company | FDA (EUA); WHO emergency use listing (EUL) WHO-approved in 124 countries | 70% efficacy. 46 trials in 3 countries. Phase II/III was completed in June 2021; Phase IV was registered on 27 September 2021 [26] |
[4,16,21,22,23,24,26] |
| Sputnik V | Gam-COVID-Vac | Adenoviral-based vaccine | Gamaleya National Research Centre of Epidemiology and Microbiology (Moscow, Russia) | FDA (EUA) | 91.6% efficacy; | [25,27,28,30] |
| Convidecia/CanSino | Ad5-nCoV Vaccine | The recombinant vaccine which involves replication-defective adenovirus type 5 as vector | Tianjin, China in collaboration with the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences | - | 90% efficacy. Phase IV registered in May 2021 |
[20,27,30] |
| Covaxin Vaccine | BBV152 | Inactivated vaccine candidate; deactivated rabies vaccine as a vehicle for coronavirus proteins | Bharat Biotech (India) in collaboration with Thomas Jefferson University of Philadelphia, Indian Council of Medical Research (ICMR) and National Institute of Virology (Pune, India) | FDA (EUA) | - | [25,27] |
| Sinopharm | New Crown COVID-19 Vaccine | Inactivated vaccine candidate | Wuhan Institute of Biological Products, (China) | FDA (EUA); WHO (EUL); WHO-approved in 68 countries | 79.34% efficacy. 15 trials in 9 countries |
[20,25,26,27,28,30] |
| Sinovac/CoronaVac | CoronaVac Vaccine | Adsorbed (inactivated) vaccine | Sinovac Life Sciences Co. Ltd. (China) in collaboration with Instituto Butantan | WHO emergency use listing (EUL); WHO-approved in 41 countries | 65% efficacy; 22 trials in 2 countries. Phase IV registered on 27 September 2021 |
[20,26,27,30] |
| Covishield | AZD1222 | (Oxford/ AstraZeneca formulation) |
Serum Institute of India | WHO-approved in 46 countries? | 2 trials in 1 country | [26] |
| Novavax | NVX-CoV2373 | Antigenic components (spike (S) protein) generated in vitro (Viral subunit) | - | - | - | [30,31] |